2f:I[703058,["/_next/static/immutable/chunks/2esyeua7r8hxb.js","/_next/static/immutable/chunks/43wzqu_q6b8co.js","/_next/static/immutable/chunks/02igegklyi312.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/3d54cr_x61503.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/41sb2pnxui1_7.js","/_next/static/immutable/chunks/0z5fu495o1bws.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T41e,Highlights across studies: - **Atopic march ML model:** Simplified models using routine early-life clinical features accurately predicted moderate-to-severe persistent asthma/allergic rhinitis by ages 5–11. - **Peanut OIT (IMPACT follow-up):** 80% of children who received pnOIT only (group A, n=40) were eating peanut at follow-up; 35% of group A reported peanut reactions since IMPACT; IgG4:IgE ratio remained higher in the pnOIT group vs. placebo years later. - **Dupilumab & autoimmunity in children:** Cutaneous autoimmune diagnoses (mainly psoriasis and alopecia areata) were ~2 per 1,000 children/year higher in the dupilumab group; no significant differences in endocrine, GI, or rheumatologic autoimmune diagnoses. - **EoE transcriptome:** Dupilumab normalized >1,300 dysregulated EoE genes (eosinophil and non-eosinophil pathways) across all age groups, sustained on treatment. - **α-Gal IgG & atherosclerosis:** Anti-α-Gal IgG formed immune complexes with α-Gal–bearing LDL, enhancing macrophage uptake and foam cell formation in vitro.31:T5e5,Airway hyper-responsiveness (AHR) is well established in asthma but remains under-recognized in chronic obstructive pulmonary disease (COPD). The recognition of COPD heterogeneity, particularly eosinophilic COPD and asthma COPD overlap, has increased interest in AHR as a clinical marker of type 2 (T2) inflammation. This phenotype is present in 20% to 40% of patients with COPD and has become a focus of clinical trials exploring biologics targeting IL-4, IL-5, IL-13, and thymic stromal lymphopoietin. We aim to review current evidence on AHR in COPD, its relationship with inflammatory phenotypes, diagnostic modalities, and therapeutic implications. AHR in COPD reflects both structural and inflammatory mechanisms. Direct challenges such as methacholine predominantly assess airway geometry, whereas indirect challenges such as mannitol reflect more activity of T2 inflammation and correlates consequently with eosinophils and fractional exhaled nitric oxide. Patients with AHR may derive greater benefit from inhaled corticosteroids than AHR-negative patients. Although AHR reduction has been demonstrated with biologics in asthma, no study has evaluated their effects on AHR in COPD. AHR represents a clinically relevant and promising treatable trait in COPD, particularly in T2-high phenotypes. Standardized challenges combined with the integration of inflammatory markers and targeted trials of biologics are needed to clarify its role in personalized COPD management and therapeutic decision-making.32:T611,This scoping review aimed to explore psychological and related biopsychosocial factors influencing adherence to biologic therapies among individuals with asthma. Despite the proven efficacy of biologics for severe type 2 inflammation, real-world adherence remains variable. The review sought to identify individual, clinical, and contextual determinants that facilitate or hinder adherence behaviors. A systematic search of PubMed, Scopus, and APA PsycINFO identified 14 studies published between 2018 and 2025. Most were observational or retrospective and conducted in the United States. Adherence rates were generally moderate to high but varied across biologics. Systemic barriers included high out-of-pocket costs, complex insurance procedures, and limited access to specialist care. Clinically, patients with milder symptoms or low perceived treatment benefit were more likely to discontinue. Psychological barriers-such as fear of injections, illness denial, depression, and stigma-were recurrent yet understudied. Facilitators included perceived efficacy, emotional reassurance, shared decision-making, and supportive treatment settings. Adherence to biologic therapies in asthma reflects a multidimensional interplay between systemic, clinical, and psychological influences. Integrating psychological assessment, patient education, and system-level support is essential to sustain long-term engagement. Future research should address psychological mechanisms and develop tailored interventions to enhance adherence and improve clinical outcomes.33:T808,Abstract Purpose of Review This scoping review aimed to explore psychological and related biopsychosocial factors influencing adherence to biologic therapies among individuals with asthma. Despite the proven efficacy of biologics for severe type 2 inflammation, real-world adherence remains variable. The review sought to identify individual, clinical, and contextual determinants that facilitate or hinder adherence behaviors. Recent Findings A systematic search of PubMed, Scopus, and APA PsycINFO identified 14 studies published between 2018 and 2025. Most were observational or retrospective and conducted in the United States. Adherence rates were generally moderate to high but varied across biologics. Systemic barriers included high out-of-pocket costs, complex insurance procedures, and limited access to specialist care. Clinically, patients with milder symptoms or low perceived treatment benefit were more likely to discontinue. Psychological barriers—such as fear of injections, illness denial, depression, and stigma—were recurrent yet understudied. Facilitators included perceived efficacy, emotional reassurance, shared decision-making, and supportive treatment settings. Summary Adherence to biologic therapies in asthma reflects a multidimensional interplay between systemic, clinical, and psychological influences. Integrating psychological assessment, patient education, and system-level support is essential to sustain long-term engagement. Future research should address psychological mechanisms and develop tailored interventions to enhance adherence and improve clinical outcomes. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Biologic in Allergy: Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed Allergy papers on Biologic (modality). Clinician-written summaries and practical action steps. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/Allergy/modality/Biologic\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Allergy Hub\",\"item\":\"https://www.reachrx.ai/hub/Allergy\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"modality: Biologic\",\"item\":\"https://www.reachrx.ai/hub/Allergy/modality/Biologic\"}]}}"}}]],["$","$L2f",null,{"title":"Biologic in Allergy Research","description":"Review Allergy evidence by treatment modality: Biologic — concise summaries and practical next steps.","papers":[{"doi":"10.1111/all.70512","pmid":"42713891","title":"Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases","journal_title":"Allergy","journal_issn":"0105-4538","published_at":"2026-09-09T00:00:00.000Z","url":"https://doi.org/10.1111/all.70512","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-14T06:23:22.965Z","updated_at":"2026-09-14T06:23:22.965Z","tags":[{"paper_doi":"10.1111/all.70512","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"condition","value":"Allergic Disease","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"condition","value":"Eosinophilic Inflammatory Disease","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"condition","value":"Type 2 Inflammatory Disease","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"modality","value":"Anti-IgE","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"modality","value":"Anti-IL-13","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"modality","value":"Anti-IL-31","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"modality","value":"Anti-IL-4","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"modality","value":"Anti-IL-5","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"modality","value":"Anti-TSLP","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"warning","value":"Evolutionary claims (e.g., IgG4 emergence ~10 million years ago) are based on the authors' synthesis of the literature and are not independently verifiable from this text alone.","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"warning","value":"No sample size applies — this is a review article with no primary patient data.","value_numeric":null},{"paper_doi":"10.1111/all.70512","tag_type":"warning","value":"The safety_signal impact flag reflects the authors' theoretical concern about long-term T2 suppression; no clinical adverse event data are reported.","value_numeric":null}],"summaries":{"what_studied":"This narrative review examines the dual role of Type 2 (T2) immunity in both homeostatic functions (tissue protection, repair, barrier maintenance) and disease (allergies, eosinophilic conditions), tracing its evolutionary origins over ~500 million years and discussing implications of long-term T2 pathway blockade with biologics.","key_result":"T2 immunity extends well beyond allergy: it supports barrier integrity, tissue repair, and host defense against parasites, co-evolving with immune-regulatory circuits up to the emergence of IgG4 in great apes (~10 million years ago). Biologics targeting IL-4, IL-5, IL-13, IL-31, TSLP, and IgE have transformed management of T2-driven diseases, but sustained suppression of these pathways raises unresolved questions about long-term homeostatic consequences.","limitations":"Narrative review without systematic search or meta-analysis; causal claims about evolutionary co-evolution are inferential; long-term safety data on T2 pathway blockade are not yet available.","practice_takeaway":"Clinicians using T2-targeting biologics should be aware that these pathways also serve protective homeostatic roles; long-term follow-up for consequences of sustained T2 suppression (e.g., infection susceptibility, barrier health, microbiome shifts) is warranted. An expanding set of T2-driven diseases beyond classic allergy may benefit from these targeted agents."}},{"doi":"10.1111/all.70466","pmid":"42618976","title":"Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations","journal_title":"Allergy","journal_issn":"0105-4538","published_at":"2026-08-19T00:00:00.000Z","url":"https://doi.org/10.1111/all.70466","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-30T06:19:56.216Z","updated_at":"2026-08-30T06:19:56.216Z","tags":[{"paper_doi":"10.1111/all.70466","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"condition","value":"Acute Generalized Exanthematous Pustulosis","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"condition","value":"Anaphylaxis","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"condition","value":"Drug Hypersensitivity","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"condition","value":"Drug Reaction with Eosinophilia and Systemic Symptoms","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"condition","value":"Maculopapular Exanthema","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"condition","value":"Stevens-Johnson Syndrome","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"condition","value":"Toxic Epidermal Necrolysis","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"modality","value":"Anesthetic","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"modality","value":"Antibiotic","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"modality","value":"Contrast Media","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"modality","value":"Proton Pump Inhibitor","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"warning","value":"Chemotherapy-specific guidance (testing within 2 weeks) differs from the general 4–6 week window; clinicians should apply the correct algorithm per drug class.","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"warning","value":"Level of evidence assigned as '3' (consensus guideline/expert panel); the paper does not report an original trial with a defined sample size, so no sample_size tag was applied.","value_numeric":null},{"paper_doi":"10.1111/all.70466","tag_type":"warning","value":"Many drug-class recommendations are 'conditional' due to sparse negative-control data, meaning specificity for those agents is not firmly established.","value_numeric":null}],"summaries":{"what_studied":"Updated EAACI guidelines standardizing skin testing methodology (prick, intradermal, patch) for immediate and non-immediate drug hypersensitivity reactions, including validated non-irritant concentrations for major drug classes and risk-stratified algorithms for drug provocation testing.","key_result":"The optimal testing window is 4–6 weeks post-reaction for immediate reactions (false negatives rise beyond 6 months); the validated intradermal test threshold is a wheal ≥ initial wheal +3 mm at 20 min after injecting exactly 0.02 mL. Risk algorithms now allow direct drug provocation for mild maculopapular exanthema, while anaphylaxis requires prior skin testing; skin tests are deemed safe and useful for DRESS/AGEP/SJS/TEN.","limitations":"Conditional recommendations are provided for many drug classes where few or no negative controls are available, limiting specificity data. Crushing tablets and diluting at 30% in petrolatum introduces significant variability in final active-ingredient concentrations.","practice_takeaway":"Test patients for immediate drug hypersensitivity 4–6 weeks post-reaction using the standardized 0.02 mL intradermal technique (wheal ≥ initial +3 mm = positive). For mild maculopapular exanthema, skin tests can be bypassed in favor of direct drug provocation, but anaphylaxis or severe cutaneous reactions (DRESS/AGEP/SJS/TEN) require skin testing first."}},{"doi":"10.1016/j.jaci.2026.06.010","pmid":null,"title":"The Editors’ Choice","journal_title":"Journal of Allergy and Clinical Immunology","journal_issn":"0091-6749","published_at":"2026-08-05T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaci.2026.06.010","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-08-11T13:26:12.518Z","updated_at":"2026-08-24T06:18:18.582Z","tags":[{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"brand","value":"Dupixent","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"condition","value":"Allergic Rhinitis","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"condition","value":"Alpha-Gal Syndrome","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"condition","value":"Asthma","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"condition","value":"Atherosclerosis","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"condition","value":"Chronic Rhinosinusitis With Nasal Polyps","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"condition","value":"Eosinophilic Esophagitis","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"condition","value":"Peanut Allergy","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"generic","value":"dupilumab","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"modality","value":"Machine Learning / Predictive Modeling","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"modality","value":"Oral Immunotherapy","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"sample_size","value":"n=10000","value_numeric":10000},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"study_design","value":"Editorial / Editors' Choice (Multi-Study Summary)","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"Level of evidence reflects the strongest individual study design cited (validated ML cohort study / long-term RCT follow-up); other highlighted studies range from cross-sectional to in vitro mechanistic.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"Only a publisher landing/navigation page was provided — no abstract, methods, results, or conclusions are accessible. The paper title is 'The Editors' Choice,' which is likely a curated editorial or highlights section rather than an original research article. No structured content, study design, population, or outcomes could be extracted. Full text access is required to generate meaningful summaries or tags.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"The IMPACT peanut OIT follow-up had a 54% participation rate, which may affect generalizability of long-term outcomes.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"The paper provided contains only a DOI, URL, journal name, and publication date — no abstract, methods, results, or any other substantive content. Structured summaries and tags cannot be generated without source text. Please provide the full text or abstract of the article for accurate extraction.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"The paper provided contains only metadata (DOI, URL, journal, and publication date) with no abstract, body text, or results. No clinical content could be extracted. Please provide the full text or abstract to generate meaningful summaries and tags.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"The paper provided contains only metadata (title, DOI, journal, and publication date) with no abstract, methods, results, or discussion. No structured summary, tags, or evidence-based content can be extracted. Please provide the full paper text to enable meaningful analysis.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"The provided source text contains only metadata (DOI, URL, journal name, and publication date) with no abstract, body text, methods, results, or conclusions. Structured summaries and tags cannot be extracted without substantive content. The paper is titled 'The Editors' Choice,' which is typically an editorial or curated highlight piece — its specific focus, population, intervention, and results are entirely unknown from the information provided.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"The provided source text contains only metadata (DOI, URL, journal name, and publication date) with no abstract, body text, or results. All summary fields and tags have been left null or empty because no content can be extracted or inferred without speculating. Please provide the full paper text for a complete structured extraction.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"The title 'The Editors' Choice' is a generic editorial section label, not a specific study title. It is unclear which article(s) or topic(s) are being referenced.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"The α-Gal/foam cell findings are in vitro only; clinical cardiovascular implications should not be overstated.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.010","tag_type":"warning","value":"This is an Editors' Choice summary article covering six distinct original studies, not a single primary study — tags and sample sizes reflect the most prominent individual studies cited, not a single pooled population.","value_numeric":null}],"summaries":{"what_studied":"This Editors' Choice issue highlights six original studies covering: (1) ML-based prediction of the atopic march in >10,000 children with early-onset atopic dermatitis; (2) CD25 as a marker of activated MCTCs in chronic rhinosinusitis with nasal polyps; (3) long-term follow-up (~8–11 years) of the IMPACT peanut oral immunotherapy trial in children aged 1–3 years; (4) rates of new autoimmune diagnoses in children ages 6–17 with atopic disease on vs. off dupilumab (PEDSnet, 10 sites, 4-year follow-up); (5) dupilumab's effect on the EoE transcriptome across pediatric, adolescent, and adult patients; and (6) anti-α-Gal IgG antibodies as a mechanistic link between α-Gal sensitization and atherosclerosis.","key_result":"$30","limitations":"- The atopic march ML study and dupilumab/autoimmunity study are both EHR-based and observational, limiting causal inference and subject to coding/ascertainment bias.\n- The IMPACT long-term follow-up enrolled only 78 of 146 original participants (54%), introducing potential selection bias.\n- The α-Gal/atherosclerosis mechanism was demonstrated in vitro only; in vivo cardiovascular relevance remains unproven.","practice_takeaway":"Early-life clinical features (respiratory symptoms, allergy meds, sensitization) can be used to flag young children with eczema for closer monitoring before asthma develops. Children on dupilumab should continue standard longitudinal monitoring for cutaneous autoimmune conditions such as psoriasis and alopecia areata, while being reassured that systemic autoimmune risks appear low."}},{"doi":"10.1016/j.jaci.2026.06.012","pmid":"42379525","title":"Dupilumab outcomes in pediatric asthma by early eosinophil status: Post hoc analysis of VOYAGE/EXCURSION","journal_title":"Journal of Allergy and Clinical Immunology","journal_issn":"0091-6749","published_at":"2026-06-30T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaci.2026.06.012","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-07T06:30:44.195Z","updated_at":"2026-09-07T06:30:44.195Z","tags":[{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"age_group","value":"child","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"brand","value":"Dupixent","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"condition","value":"Eosinophilia","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"condition","value":"Pediatric Asthma","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"condition","value":"Type 2 Asthma","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"generic","value":"dupilumab","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"modality","value":"IL-4/IL-13 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"sample_size","value":"n=156","value_numeric":156},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"study_design","value":"Post Hoc Analysis of Randomized Controlled Trial with Open-Label Extension","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"warning","value":"Level of evidence is rated 3 due to the post hoc and open-label extension design, despite originating from an RCT (VOYAGE).","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"warning","value":"The early eosinophil increase subgroup was small (n=35, 22.4% of 156), limiting statistical power for safety and efficacy comparisons.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"warning","value":"The impact_flag 'safety_signal' is used here in a reassuring direction — the signal is the absence of harm from transient eosinophilia, not a new adverse finding.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.06.012","tag_type":"warning","value":"This is a post hoc subgroup analysis; results should be interpreted as hypothesis-generating rather than confirmatory.","value_numeric":null}],"summaries":{"what_studied":"This post hoc analysis of the VOYAGE RCT and EXCURSION open-label extension evaluated long-term dupilumab efficacy and safety in children aged 6–11 with type 2 asthma, specifically in subgroups with and without early blood eosinophil increases (baseline <500 cells/μL rising to ≥500 cells/μL by week 12), over up to 2 years.","key_result":"At VOYAGE week 12, 22.4% (35/156) of dupilumab-treated children had an early eosinophil increase (≥500 cells/μL). Dupilumab reduced severe exacerbation rates vs. placebo in both subgroups, with sustained improvements in FEV1, ACQ-5-IA score, FeNO, and total IgE — and no safety differences observed between subgroups.","limitations":"Post hoc subgroup analysis limits causal inference; sample sizes within subgroups (especially early eosinophil increase group, n=35) are small; open-label extension design introduces potential bias.","practice_takeaway":"Clinicians can reassure families that early transient eosinophil rises on dupilumab do not appear to affect efficacy or safety outcomes in children with type 2 asthma. Dupilumab benefits on exacerbations, lung function, and asthma control were consistent regardless of early eosinophil status."}},{"doi":"10.1016/j.jaip.2025.10.033","pmid":"41513335","title":"Revisiting Type 2 Inflammation and Airway Hyper-responsiveness in COPD","journal_title":"The Journal of Allergy and Clinical Immunology: In Practice","journal_issn":"2213-2198","published_at":"2026-01-10T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaip.2025.10.033","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-11","doi":"10.1016/j.jaip.2025.10.033","days":"7","issn":"2213-2198","rank":"6","field":"Clinical Medicine","score":"1","category":"Allergy","categories":["Allergy"],"_categories":["Allergy"]},"pubmed":{"doi":"10.1016/j.jaip.2025.10.033","title":"Revisiting Type 2 Inflammation and Airway Hyper-responsiveness in COPD.","journal":"The journal of allergy and clinical immunology. In practice","methods":"","results":"","abstract":"$31","keywords":["Airway hyper-responsiveness","Asthma COPD overlap","COPD","Type 2 inflammation"],"pubmed_id":"41513335","conclusions":"","publication_date":"2026-01-10T00:00:00"},"crossref":{"DOI":"10.1016/j.jaip.2025.10.033","URL":"https://doi.org/10.1016/j.jaip.2025.10.033","ISSN":["2213-2198"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S2213219825010207?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S2213219825010207?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"67-75","type":"journal-article","issue":"1","score":1,"title":["Revisiting Type 2 Inflammation and Airway Hyper-responsiveness in COPD"],"author":[{"given":"Philipp","family":"Suter","sequence":"first","affiliation":[]},{"given":"Robert","family":"Greig","sequence":"additional","affiliation":[]},{"given":"Rory","family":"Chan","sequence":"additional","affiliation":[]},{"given":"Brian J.","family":"Lipworth","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,1]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"14","created":{"date-time":"2026-01-07T09:14:41Z","timestamp":1767777281000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-07T13:34:06Z","timestamp":1767792846686,"date-parts":[[2026,1,7]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000,"date-parts":[[2025,11,15]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S2213219825010207"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Revisiting Type 2 Inflammation and Airway Hyper-responsiveness in COPD"},{"name":"journaltitle","label":"Journal Title","value":"The Journal of Allergy and Clinical Immunology: In Practice"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaip.2025.10.033"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology."}],"deposited":{"date-time":"2026-01-07T09:49:48Z","timestamp":1767779388000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"2213-2198"}],"published":{"date-parts":[[2026,1]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/j.jaip.2023.12.013","key":"10.1016/j.jaip.2025.10.033_bib1","year":"2024","issue":null,"author":"Lipworth","volume":"12","first-page":"904","unstructured":null,"article-title":"Should airway hyper-responsiveness be included in the definition of clinical remission with biologic therapy in severe asthma","journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ebiom.2024.105453","key":"10.1016/j.jaip.2025.10.033_bib2","year":"2024","issue":null,"author":"Fangal","volume":"110","first-page":null,"unstructured":null,"article-title":"Distinct physiological, transcriptomic, and imaging characteristics of asthma-COPD overlap compared to asthma and COPD in smokers","journal-title":"EBioMedicine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaip.2022.04.034","key":"10.1016/j.jaip.2025.10.033_bib3","year":"2022","issue":null,"author":"Thomson","volume":"10","first-page":"2783","unstructured":null,"article-title":"Cigarette smoking and asthma","journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMra1411863","key":"10.1016/j.jaip.2025.10.033_bib4","year":"2015","issue":null,"author":"Postma","volume":"373","first-page":"1241","unstructured":null,"article-title":"The asthma-COPD overlap syndrome","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.rmed.2011.11.003","key":"10.1016/j.jaip.2025.10.033_bib5","year":"2012","issue":null,"author":"Tamimi","volume":"106","first-page":"319","unstructured":null,"article-title":"The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications","journal-title":"Respir Med","doi-asserted-by":"crossref"},{"DOI":"10.3390/jpm12081231","key":"10.1016/j.jaip.2025.10.033_bib6","year":"2022","issue":null,"author":"Bellou","volume":"12","first-page":"1231","unstructured":null,"article-title":"Asthma and tobacco smoking","journal-title":"J Pers Med","doi-asserted-by":"crossref"},{"DOI":"10.1183/09031936.00073312","key":"10.1016/j.jaip.2025.10.033_bib7","year":"2013","issue":null,"author":"Polosa","volume":"41","first-page":"716","unstructured":null,"article-title":"Smoking and asthma: dangerous liaisons","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.mam.2021.101021","key":"10.1016/j.jaip.2025.10.033_bib8","year":"2022","issue":null,"author":"Morissette","volume":"85","first-page":null,"unstructured":null,"article-title":"Asthma COPD overlap: insights into cellular and molecular mechanisms","journal-title":"Mol Aspects Med","doi-asserted-by":"crossref"},{"DOI":"10.1183/13993003.04656-2020","key":"10.1016/j.jaip.2025.10.033_bib9","year":"2021","issue":null,"author":"Marcon","volume":"58","first-page":null,"unstructured":null,"article-title":"The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1164/rccm.202303-0455CI","key":"10.1016/j.jaip.2025.10.033_bib10","year":"2023","issue":null,"author":"Rabe","volume":"208","first-page":"395","unstructured":null,"article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1183/23120541.00177-2024","key":"10.1016/j.jaip.2025.10.033_bib11","year":"2024","issue":null,"author":"Wechsler","volume":"10","first-page":"00177","unstructured":null,"article-title":"What every clinician should know about inflammation in COPD","journal-title":"ERJ Open Res","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41577-018-0006-6","key":"10.1016/j.jaip.2025.10.033_bib12","year":"2018","issue":null,"author":"Barnes","volume":"18","first-page":"454","unstructured":null,"article-title":"Targeting cytokines to treat asthma and chronic obstructive pulmonary disease","journal-title":"Nat Rev Immunol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaip.2025.10.033_bib13","year":"2024","issue":null,"author":"Beech","volume":"20","first-page":null,"unstructured":null,"article-title":"Type 2 inflammation in COPD: is it just asthma?","journal-title":"Breathe (Sheff)","doi-asserted-by":null},{"DOI":"10.1056/NEJMoa2401304","key":"10.1016/j.jaip.2025.10.033_bib14","year":"2024","issue":null,"author":"Bhatt","volume":"390","first-page":"2274","unstructured":null,"article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2303951","key":"10.1016/j.jaip.2025.10.033_bib15","year":"2023","issue":null,"author":"Bhatt","volume":"389","first-page":"205","unstructured":null,"article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2413181","key":"10.1016/j.jaip.2025.10.033_bib16","year":"2025","issue":null,"author":"Sciurba","volume":"392","first-page":"1710","unstructured":null,"article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.3389/fphar.2019.00765","key":"10.1016/j.jaip.2025.10.033_bib17","year":"2019","issue":null,"author":"Kume","volume":"10","first-page":"765","unstructured":null,"article-title":"Eosinophil inflammation and hyperresponsiveness in the airways as phenotypes of COPD, and usefulness of inhaled glucocorticosteroids","journal-title":"Front Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1183/09031936.00169711","key":"10.1016/j.jaip.2025.10.033_bib18","year":"2012","issue":null,"author":"van den Berge","volume":"40","first-page":"1098","unstructured":null,"article-title":"Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1183/09041950.053s1693","key":"10.1016/j.jaip.2025.10.033_bib19","year":"1993","issue":null,"author":"Sterk","volume":"16","first-page":"53","unstructured":null,"article-title":null,"journal-title":"Eur Respir J Suppl","doi-asserted-by":"crossref"},{"DOI":"10.1378/chest.123.3_suppl.411S","key":"10.1016/j.jaip.2025.10.033_bib20","year":"2003","issue":"Suppl","author":"O'Byrne","volume":"123","first-page":"411S","unstructured":null,"article-title":"Airway hyperresponsiveness","journal-title":"Chest","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaci.2006.07.012","key":"10.1016/j.jaip.2025.10.033_bib21","year":"2006","issue":null,"author":"Cockcroft","volume":"118","first-page":"551","unstructured":null,"article-title":"Mechanisms of airway hyperresponsiveness","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1186/1465-9921-12-11","key":"10.1016/j.jaip.2025.10.033_bib22","year":"2011","issue":null,"author":"de Nijs","volume":"12","first-page":"11","unstructured":null,"article-title":"Airway inflammation and mannitol challenge test in COPD","journal-title":"Respir Res","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaip.2025.10.033_bib23","year":"2010","issue":null,"author":"Dima","volume":"5","first-page":"287","unstructured":null,"article-title":"Pulmonary function tests, sputum induction, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice","journal-title":"Int J Chron Obstruct Pulmon Dis","doi-asserted-by":null},{"DOI":"10.1016/j.ejcdt.2014.01.006","key":"10.1016/j.jaip.2025.10.033_bib24","year":"2014","issue":null,"author":"Hantera","volume":"63","first-page":"351","unstructured":null,"article-title":"Methacholine challenge test as indicator for add on inhaled corticosteroids in COPD patients","journal-title":"Egypt J Chest Dis Tuberc","doi-asserted-by":"crossref"},{"DOI":"10.1164/ajrccm.150.4.7921469","key":"10.1016/j.jaip.2025.10.033_bib25","year":"1994","issue":null,"author":"Kanner","volume":"150","first-page":"956","unstructured":null,"article-title":"Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1378/chest.110.3.632","key":"10.1016/j.jaip.2025.10.033_bib26","year":"1996","issue":null,"author":"Koskela","volume":"110","first-page":"632","unstructured":null,"article-title":"Bronchoconstriction due to cold weather in COPD. The roles of direct airway effects and cutaneous reflex mechanisms","journal-title":"Chest","doi-asserted-by":"crossref"},{"DOI":"10.1080/15412550802093009","key":"10.1016/j.jaip.2025.10.033_bib27","year":"2008","issue":null,"author":"Kostikas","volume":"5","first-page":"171","unstructured":null,"article-title":"Isocapnic cold air challenge in patients with COPD: are there any predisposing factors?","journal-title":"COPD","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.pupt.2004.10.005","key":"10.1016/j.jaip.2025.10.033_bib28","year":"2005","issue":null,"author":"Leuppi","volume":"18","first-page":"83","unstructured":null,"article-title":"Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept","journal-title":"Pulm Pharmacol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1164/ajrccm/147.3.553","key":"10.1016/j.jaip.2025.10.033_bib29","year":"1993","issue":null,"author":"Oosterhoff","volume":"147","first-page":"553","unstructured":null,"article-title":"Airway responsiveness to adenosine 5'-monophosphate in chronic obstructive pulmonary disease is determined by smoking","journal-title":"Am Rev Respir Dis","doi-asserted-by":"crossref"},{"DOI":"10.1080/15412555.2019.1675150","key":"10.1016/j.jaip.2025.10.033_bib30","year":"2019","issue":null,"author":"Proboszcz","volume":"16","first-page":"354","unstructured":null,"article-title":"Relationship between blood and induced sputum eosinophils, bronchial hyperresponsiveness and reversibility of airway obstruction in mild-to-moderate chronic obstructive pulmonary disease","journal-title":"COPD","doi-asserted-by":"crossref"},{"DOI":"10.1136/thx.39.12.912","key":"10.1016/j.jaip.2025.10.033_bib31","year":"1984","issue":null,"author":"Ramsdale","volume":"39","first-page":"912","unstructured":null,"article-title":"Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness","journal-title":"Thorax","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaip.2025.10.033_bib32","year":"1982","issue":null,"author":"Ramsdell","volume":"126","first-page":"829","unstructured":null,"article-title":"Bronchial hyperreactivity in chronic obstructive bronchitis","journal-title":"Am Rev Respir Dis","doi-asserted-by":null},{"DOI":"10.1046/j.1365-2222.2000.00819.x","key":"10.1016/j.jaip.2025.10.033_bib33","year":"2000","issue":null,"author":"Rutgers","volume":"30","first-page":"657","unstructured":null,"article-title":"Airway inflammation and hyperresponsiveness to adenosine 5'-monophosphate in chronic obstructive pulmonary disease","journal-title":"Clin Exp Allergy","doi-asserted-by":"crossref"},{"DOI":"10.1034/j.1399-3003.2000.15b07.x","key":"10.1016/j.jaip.2025.10.033_bib34","year":"2000","issue":null,"author":"Sanchez-Toril","volume":"15","first-page":"260","unstructured":null,"article-title":"Differences in airway responsiveness to acetaldehyde and methacholine in asthma and chronic bronchitis","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1378/chest.11-2535","key":"10.1016/j.jaip.2025.10.033_bib35","year":"2012","issue":null,"author":"Scherr","volume":"142","first-page":"919","unstructured":null,"article-title":"Response to add-on inhaled corticosteroids in COPD based on airway hyperresponsiveness to mannitol","journal-title":"Chest","doi-asserted-by":"crossref"},{"DOI":"10.1164/ajrccm/145.2_Pt_1.301","key":"10.1016/j.jaip.2025.10.033_bib36","year":"1992","issue":"Pt. 1","author":"Tashkin","volume":"145","first-page":"301","unstructured":null,"article-title":"The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group","journal-title":"Am Rev Respir Dis","doi-asserted-by":"crossref"},{"DOI":"10.1080/15412550500493360","key":"10.1016/j.jaip.2025.10.033_bib37","year":"2006","issue":null,"author":"Taube","volume":"3","first-page":"25","unstructured":null,"article-title":"Isolated bronchi of patients with COPD show decreased histamine responsiveness compared to smokers with normal lung function","journal-title":"COPD","doi-asserted-by":"crossref"},{"DOI":"10.1183/13993003.01378-2019","key":"10.1016/j.jaip.2025.10.033_bib38","year":"2020","issue":null,"author":"Teferra","volume":"55","first-page":null,"unstructured":null,"article-title":"Longitudinal changes in airway hyperresponsiveness and COPD mortality","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaci.2016.04.022","key":"10.1016/j.jaip.2025.10.033_bib39","year":"2016","issue":null,"author":"Tkacova","volume":"138","first-page":"1571","unstructured":null,"article-title":"Airway hyperresponsiveness in chronic obstructive pulmonary disease: a marker of asthma-chronic obstructive pulmonary disease overlap syndrome?","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1183/09031936.04.00117603","key":"10.1016/j.jaip.2025.10.033_bib40","year":"2004","issue":null,"author":"Willemse","volume":"24","first-page":"391","unstructured":null,"article-title":"Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1378/chest.124.2.449","key":"10.1016/j.jaip.2025.10.033_bib41","year":"2003","issue":null,"author":"Wise","volume":"124","first-page":"449","unstructured":null,"article-title":"The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study","journal-title":"Chest","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM200012283432601","key":"10.1016/j.jaip.2025.10.033_bib42","year":"2000","issue":null,"author":"Lung Health Study Research Group","volume":"343","first-page":"1902","unstructured":null,"article-title":"Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaip.2025.10.033_bib43","year":"1985","issue":null,"author":"Yan","volume":"132","first-page":"25","unstructured":null,"article-title":"Prevalence and nature of bronchial hyperresponsiveness in subjects with chronic obstructive pulmonary disease","journal-title":"Am Rev Respir Dis","doi-asserted-by":null},{"DOI":"10.1186/s40001-025-02492-9","key":"10.1016/j.jaip.2025.10.033_bib44","year":"2025","issue":null,"author":"Yang","volume":"30","first-page":"223","unstructured":null,"article-title":"Chronic airway inflammatory diseases and e-cigarette use: a review of health risks and mechanisms","journal-title":"Eur J Med Res","doi-asserted-by":"crossref"},{"DOI":"10.2147/COPD.S80992","key":"10.1016/j.jaip.2025.10.033_bib45","year":"2015","issue":null,"author":"Zanini","volume":"10","first-page":"1155","unstructured":null,"article-title":"Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease","journal-title":"Int J Chron Obstruct Pulmon Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaip.2025.10.033_bib46","year":"1999","issue":null,"author":"Costello","volume":"276","first-page":"L709","unstructured":null,"article-title":"Antigen-induced hyperreactivity to histamine: role of the vagus nerves and eosinophils","journal-title":"Am J Physiol","doi-asserted-by":null},{"DOI":"10.1007/s00408-012-9448-y","key":"10.1016/j.jaip.2025.10.033_bib47","year":"2013","issue":null,"author":"Blomstrand","volume":"191","first-page":"183","unstructured":null,"article-title":"Bronchial responsiveness to dry air hyperventilation in smokers may predict decline in airway status using indirect methods","journal-title":"Lung","doi-asserted-by":"crossref"},{"DOI":"10.1183/09031936.03.00113403","key":"10.1016/j.jaip.2025.10.033_bib48","year":"2003","issue":null,"author":"Brannan","volume":"22","first-page":"491","unstructured":null,"article-title":"Evidence of mast cell activation and leukotriene release after mannitol inhalation","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.3109/15412551003631741","key":"10.1016/j.jaip.2025.10.033_bib49","year":"2010","issue":null,"author":"Hassan","volume":"7","first-page":"133","unstructured":null,"article-title":"Airway responsiveness to indirect challenges in COPD","journal-title":"COPD","doi-asserted-by":"crossref"},{"DOI":"10.1016/0007-0971(75)90090-X","key":"10.1016/j.jaip.2025.10.033_bib50","year":"1975","issue":null,"author":"Benson","volume":"69","first-page":"227","unstructured":null,"article-title":"Bronchial hyperreactivity","journal-title":"Br J Dis Chest","doi-asserted-by":"crossref"},{"DOI":"10.1152/ajplung.00325.2018","key":"10.1016/j.jaip.2025.10.033_bib51","year":"2019","issue":null,"author":"Maarsingh","volume":"316","first-page":"L537","unstructured":null,"article-title":"Small airway hyperresponsiveness in COPD: relationship between structure and function in lung slices","journal-title":"Am J Physiol Lung Cell Mol Physiol","doi-asserted-by":"crossref"},{"DOI":"10.1164/ajrccm.158.supplement_2.13tac170","key":"10.1016/j.jaip.2025.10.033_bib52","year":"1998","issue":"Pt. 3","author":"Postma","volume":"158","first-page":"S187","unstructured":null,"article-title":"Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaip.2025.10.033_bib53","year":"2006","issue":null,"author":"Scichilone","volume":"1","first-page":"49","unstructured":null,"article-title":"Clinical implications of airway hyperresponsiveness in COPD","journal-title":"Int J Chron Obstruct Pulmon Dis","doi-asserted-by":null},{"DOI":"10.1152/japplphysiol.00209.2002","key":"10.1016/j.jaip.2025.10.033_bib54","year":"2002","issue":null,"author":"Crimi","volume":"93","first-page":"1384","unstructured":null,"article-title":"Deep breaths, methacholine, and airway narrowing in healthy and mild asthmatic subjects","journal-title":"J Appl Physiol (1985)","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12931-023-02538-8","key":"10.1016/j.jaip.2025.10.033_bib55","year":"2023","issue":null,"author":"Yasuda","volume":"24","first-page":"250","unstructured":null,"article-title":"Critical roles of airway smooth muscle in mediating deep-inspiration-induced bronchodilation: a big stretch?","journal-title":"Respir Res","doi-asserted-by":"crossref"},{"DOI":"10.1378/chest.125.6.2029","key":"10.1016/j.jaip.2025.10.033_bib56","year":"2004","issue":null,"author":"Scichilone","volume":"125","first-page":"2029","unstructured":null,"article-title":"Bronchodilatory effect of deep inspiration is absent in subjects with mild COPD","journal-title":"Chest","doi-asserted-by":"crossref"},{"DOI":"10.1152/japplphysiol.01307.2007","key":"10.1016/j.jaip.2025.10.033_bib57","year":"2008","issue":null,"author":"Scichilone","volume":"105","first-page":"832","unstructured":null,"article-title":"The airway response to deep inspirations decreases with COPD severity and is associated with airway distensibility assessed by computed tomography","journal-title":"J Appl Physiol (1985)","doi-asserted-by":"crossref"},{"DOI":"10.1111/resp.12841","key":"10.1016/j.jaip.2025.10.033_bib58","year":"2016","issue":null,"author":"Jones","volume":"21","first-page":"1347","unstructured":null,"article-title":"Airway remodelling in COPD: it's not asthma","journal-title":"Respirology","doi-asserted-by":"crossref"},{"DOI":"10.1164/ajrccm.160.1.9811015","key":"10.1016/j.jaip.2025.10.033_bib59","year":"1999","issue":null,"author":"Jansen","volume":"160","first-page":"259","unstructured":null,"article-title":"Smoking and airway hyperresponsiveness especially in the presence of blood eosinophilia increase the risk to develop respiratory symptoms: a 25-year follow-up study in the general adult population","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(00)02815-4","key":"10.1016/j.jaip.2025.10.033_bib60","year":"2000","issue":null,"author":"Hospers","volume":"356","first-page":"1313","unstructured":null,"article-title":"Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1136/bjsm.35.5.344","key":"10.1016/j.jaip.2025.10.033_bib61","year":"2001","issue":null,"author":"Anderson","volume":"35","first-page":"344","unstructured":null,"article-title":"Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction","journal-title":"Br J Sports Med","doi-asserted-by":"crossref"},{"DOI":"10.1089/08942680152007855","key":"10.1016/j.jaip.2025.10.033_bib62","year":"2001","issue":null,"author":"Kohlhaufl","volume":"14","first-page":"1","unstructured":null,"article-title":"Impulse oscillometry in healthy nonsmokers and asymptomatic smokers: effects of bronchial challenge with methacholine","journal-title":"J Aerosol Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.rmed.2005.01.006","key":"10.1016/j.jaip.2025.10.033_bib63","year":"2005","issue":null,"author":"Broeders","volume":"99","first-page":"1046","unstructured":null,"article-title":"Bronchial challenge, assessed with forced expiratory manoeuvres and airway impedance","journal-title":"Respir Med","doi-asserted-by":"crossref"},{"DOI":"10.1042/CS20160253","key":"10.1016/j.jaip.2025.10.033_bib64","year":"2017","issue":null,"author":"Russell","volume":"131","first-page":"1723","unstructured":null,"article-title":"Pathogenesis of asthma: implications for precision medicine","journal-title":"Clin Sci (Lond)","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.anai.2023.02.016","key":"10.1016/j.jaip.2025.10.033_bib65","year":"2023","issue":null,"author":"Chan","volume":"131","first-page":"37","unstructured":null,"article-title":"Efficacy of biologic therapy on airway hyperresponsiveness in asthma","journal-title":"Ann Allergy Asthma Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2213-2600(25)00044-X","key":"10.1016/j.jaip.2025.10.033_bib66","year":"2025","issue":null,"author":"Christenson","volume":"13","first-page":"687","unstructured":null,"article-title":"Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial","journal-title":"Lancet Respir Med","doi-asserted-by":"crossref"},{"DOI":"10.1183/09031936.00129912","key":"10.1016/j.jaip.2025.10.033_bib67","year":"2012","issue":null,"author":"Irvin","volume":"40","first-page":"1067","unstructured":null,"article-title":"Neutrophils, airway hyperresponsiveness and COPD: true, true and related?","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaci.2024.11.024","key":"10.1016/j.jaip.2025.10.033_bib68","year":"2025","issue":null,"author":"Stewart","volume":"155","first-page":"834","unstructured":null,"article-title":"Effects of dupilumab on mannitol airway hyperresponsiveness in uncontrolled severe asthma","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2213-2600(21)00226-5","key":"10.1016/j.jaip.2025.10.033_bib69","year":"2021","issue":null,"author":"Diver","volume":"9","first-page":"1299","unstructured":null,"article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","journal-title":"Lancet Respir Med","doi-asserted-by":"crossref"},{"DOI":"10.1183/13993003.01296-2021","key":"10.1016/j.jaip.2025.10.033_bib70","year":"2022","issue":null,"author":"Sverrild","volume":"59","first-page":null,"unstructured":null,"article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1111/all.16283","key":"10.1016/j.jaip.2025.10.033_bib71","year":"2024","issue":null,"author":"Chan","volume":"79","first-page":"2873","unstructured":null,"article-title":"Indirect case-matched comparison of anti-IL4Ralpha versus anti-IL5Ralpha on airway hyperresponsiveness","journal-title":"Allergy","doi-asserted-by":"crossref"},{"DOI":"10.2147/JAA.S410592","key":"10.1016/j.jaip.2025.10.033_bib72","year":"2023","issue":null,"author":"Spahn","volume":"16","first-page":"755","unstructured":null,"article-title":"Effect of biologic therapies on airway hyperresponsiveness and allergic response: a systematic literature review","journal-title":"J Asthma Allergy","doi-asserted-by":"crossref"},{"DOI":"10.1111/all.16537","key":"10.1016/j.jaip.2025.10.033_bib73","year":"2025","issue":null,"author":"Lipworth","volume":"80","first-page":"1226","unstructured":null,"article-title":"Head-to-head comparison of biologic efficacy in asthma: what have we learned?","journal-title":"Allergy","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaci.2019.10.037","key":"10.1016/j.jaip.2025.10.033_bib74","year":"2020","issue":null,"author":"Manson","volume":"145","first-page":"808","unstructured":null,"article-title":"IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1165/ajrcmb.26.2.4600","key":"10.1016/j.jaip.2025.10.033_bib75","year":"2002","issue":null,"author":"Venkayya","volume":"26","first-page":"202","unstructured":null,"article-title":"The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells","journal-title":"Am J Respir Cell Mol Biol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.rmed.2008.11.002","key":"10.1016/j.jaip.2025.10.033_bib76","year":"2009","issue":null,"author":"Walker","volume":"103","first-page":"535","unstructured":null,"article-title":"Lung function changes following methacholine inhalation in COPD","journal-title":"Respir Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(97)10041-1","key":"10.1016/j.jaip.2025.10.033_bib77","year":"1997","issue":null,"author":"Xu","volume":"350","first-page":"1431","unstructured":null,"article-title":"Airways responsiveness and development and remission of chronic respiratory symptoms in adults","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1136/thx.2005.052241","key":"10.1016/j.jaip.2025.10.033_bib78","year":"2006","issue":null,"author":"Brutsche","volume":"61","first-page":"671","unstructured":null,"article-title":"Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study","journal-title":"Thorax","doi-asserted-by":"crossref"},{"DOI":"10.1136/thoraxjnl-2017-211289","key":"10.1016/j.jaip.2025.10.033_bib79","year":"2018","issue":null,"author":"Marcon","volume":"73","first-page":"825","unstructured":null,"article-title":"Airway responsiveness to methacholine and incidence of COPD: an international prospective cohort study","journal-title":"Thorax","doi-asserted-by":"crossref"},{"DOI":"10.1164/ajrccm.153.6.8665038","key":"10.1016/j.jaip.2025.10.033_bib80","year":"1996","issue":"Pt. 1","author":"Tashkin","volume":"153","first-page":"1802","unstructured":null,"article-title":"Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1164/ajrccm.151.5.7735588","key":"10.1016/j.jaip.2025.10.033_bib81","year":"1995","issue":null,"author":"Rijcken","volume":"151","first-page":"1377","unstructured":null,"article-title":"Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaci.2013.03.040","key":"10.1016/j.jaip.2025.10.033_bib82","year":"2014","issue":null,"author":"Marcon","volume":"133","first-page":null,"unstructured":null,"article-title":"Can an airway challenge test predict respiratory diseases? A population-based international study","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1164/rccm.200511-1746OC","key":"10.1016/j.jaip.2025.10.033_bib83","year":"2007","issue":null,"author":"Lazarus","volume":"175","first-page":"783","unstructured":null,"article-title":"Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1164/rccm.200304-503OC","key":"10.1016/j.jaip.2025.10.033_bib84","year":"2003","issue":null,"author":"Chaudhuri","volume":"168","first-page":"1308","unstructured":null,"article-title":"Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1081-1206(10)61851-0","key":"10.1016/j.jaip.2025.10.033_bib85","year":"2003","issue":null,"author":"Currie","volume":"90","first-page":"560","unstructured":null,"article-title":"Determinants of airway hyperresponsiveness in mild asthma","journal-title":"Ann Allergy Asthma Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1378/chest.11-1748","key":"10.1016/j.jaip.2025.10.033_bib86","year":"2012","issue":null,"author":"Lipworth","volume":"141","first-page":"607","unstructured":null,"article-title":"A randomized primary care trial of steroid titration against mannitol in persistent asthma: STAMINA trial","journal-title":"Chest","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-2222.1999.00021.x","key":"10.1016/j.jaip.2025.10.033_bib87","year":"1999","issue":"Suppl. 2","author":"Weir","volume":"29","first-page":"125","unstructured":null,"article-title":"A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease","journal-title":"Clin Exp Allergy","doi-asserted-by":"crossref"},{"DOI":"10.1136/thx.46.5.372","key":"10.1016/j.jaip.2025.10.033_bib88","year":"1991","issue":null,"author":"Auffarth","volume":"46","first-page":"372","unstructured":null,"article-title":"Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease","journal-title":"Thorax","doi-asserted-by":"crossref"},{"DOI":"10.1183/09031936.93.02100935","key":"10.1016/j.jaip.2025.10.033_bib89","year":"1989","issue":null,"author":"Engel","volume":"2","first-page":"935","unstructured":null,"article-title":"A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1164/ajrccm.157.3.9709100","key":"10.1016/j.jaip.2025.10.033_bib90","year":"1998","issue":"Pt. 1","author":"Rutgers","volume":"157","first-page":"880","unstructured":null,"article-title":"Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5'-monophosphate in COPD","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.pupt.2013.05.002","key":"10.1016/j.jaip.2025.10.033_bib91","year":"2014","issue":null,"author":"Spicuzza","volume":"27","first-page":"70","unstructured":null,"article-title":"Airway responsiveness to adenosine after a single dose of fluticasone propionate discriminates asthma from COPD","journal-title":"Pulm Pharmacol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1136/thorax.57.8.694","key":"10.1016/j.jaip.2025.10.033_bib92","year":"2002","issue":null,"author":"Verhoeven","volume":"57","first-page":"694","unstructured":null,"article-title":"Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness","journal-title":"Thorax","doi-asserted-by":"crossref"},{"DOI":"10.1378/chest.101.2.350","key":"10.1016/j.jaip.2025.10.033_bib93","year":"1992","issue":null,"author":"Watson","volume":"101","first-page":"350","unstructured":null,"article-title":"Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction","journal-title":"Chest","doi-asserted-by":"crossref"},{"DOI":"10.1136/thx.48.4.309","key":"10.1016/j.jaip.2025.10.033_bib94","year":"1993","issue":null,"author":"Weir","volume":"48","first-page":"309","unstructured":null,"article-title":null,"journal-title":"Thorax","doi-asserted-by":"crossref"},{"DOI":"10.1136/thx.43.4.300","key":"10.1016/j.jaip.2025.10.033_bib95","year":"1988","issue":null,"author":"Britton","volume":"43","first-page":"300","unstructured":null,"article-title":"Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma","journal-title":"Thorax","doi-asserted-by":"crossref"},{"DOI":"10.1111/cea.12972","key":"10.1016/j.jaip.2025.10.033_bib96","year":"2017","issue":null,"author":"Jabbal","volume":"47","first-page":"1239","unstructured":null,"article-title":"Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma","journal-title":"Clin Exp Allergy","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S2213219825010207"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,1]]},"reference-count":96,"published-online":null,"references-count":96,"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.jaip.2025.10.033","is_oa":true,"title":"Revisiting Type 2 Inflammation and Airway Hyper-responsiveness in COPD","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-01","best_oa_location":{"url":"https://doi.org/10.1016/j.jaip.2025.10.033","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1016/j.jaip.2025.10.033"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-18T22:40:12.285Z","tags":[{"paper_doi":"10.1016/j.jaip.2025.10.033","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2025.10.033","tag_type":"condition","value":"Chronic Obstructive Pulmonary Disease","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2025.10.033","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2025.10.033","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2025.10.033","tag_type":"modality","value":"Inhaled Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2025.10.033","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2025.10.033","tag_type":"warning","value":"Design appears to be a narrative review; systematic methods are not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2025.10.033","tag_type":"warning","value":"No COPD trials have reported AHR outcomes with biologics.","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2025.10.033","tag_type":"warning","value":"The magnitude of ICS benefit in AHR-positive COPD is not quantified.","value_numeric":null}],"summaries":{"what_studied":"A review of airway hyper-responsiveness (AHR) in COPD, its links to type 2 inflammation, diagnostic challenge tests (methacholine vs mannitol), and therapeutic implications.","key_result":"A T2-high phenotype is present in 20%–40% of COPD; indirect AHR testing with mannitol aligns with eosinophils and FeNO, AHR-positive patients may benefit more from inhaled corticosteroids than AHR-negative patients, and no study has tested biologics’ effects on AHR in COPD.","limitations":"This is a review without new primary data or quantified treatment effects. No COPD trials have measured AHR outcomes with biologics, and AHR testing lacks standardized protocols.","practice_takeaway":"Consider AHR a treatable trait in COPD, particularly in T2-high phenotypes. AHR-positive patients may gain more from inhaled corticosteroids than AHR-negative patients; biologics have not yet been studied for AHR outcomes in COPD."}},{"doi":"10.1080/02770903.2025.2610346","pmid":"41454879","title":"Real-world clinical experience with benralizumab for severe eosinophilic asthma in the Czech Republic: fewer corticosteroids and better symptom control","journal_title":"Journal of Asthma","journal_issn":"0277-0903","published_at":"2025-12-27T00:00:00.000Z","url":"https://doi.org/10.1080/02770903.2025.2610346","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-01","doi":"10.1080/02770903.2025.2610346","days":"14","issn":"0277-0903","rank":"9","field":"Clinical Medicine","score":"2","category":"Allergy","categories":["Allergy"],"_categories":["Allergy"]},"pubmed":{"doi":"10.1080/02770903.2025.2610346","title":"Real-world clinical experience with benralizumab for severe eosinophilic asthma in the Czech Republic: fewer corticosteroids and better symptom control.","journal":"The Journal of asthma : official journal of the Association for the Care of Asthma","methods":"","results":"Patients in the Czech cohort (","abstract":"Benralizumab suppresses type 2 inflammation and improves outcomes of patients with severe eosinophilic asthma (SEA). We investigated real-life clinical experience with this biological therapy in Czechia to provide evidence on effectiveness in the context of the local healthcare system.\nWe have analyzed data from the Czech cohort participating in the multi-national observational study BREEZE covering 12 months before the first benralizumab dose and 56 wk after that. Eligibility included the diagnosis of SEA and at least one dose of benralizumab administered in clinical practice. Descriptive statistics were used, and changes from baseline were assessed using paired t-test or Wilcoxon signed-rank test.\nPatients in the Czech cohort (\nClinically meaningful benefits of benralizumab treatment were confirmed in the Czech cohort, especially reduction of mOCS need, decrease of exacerbations, and improvement of asthma control.","keywords":["Biological therapy","asthma control","effectiveness","exacerbation rate","maintenance oral corticosteroids","observational study"],"pubmed_id":"41454879","conclusions":"Clinically meaningful benefits of benralizumab treatment were confirmed in the Czech cohort, especially reduction of mOCS need, decrease of exacerbations, and improvement of asthma control.","publication_date":"2025-12-27T00:00:00"},"crossref":{"DOI":"10.1080/02770903.2025.2610346","URL":"https://doi.org/10.1080/02770903.2025.2610346","ISSN":["0277-0903","1532-4303"],"link":[{"URL":"https://www.tandfonline.com/doi/pdf/10.1080/02770903.2025.2610346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1-8","type":"journal-article","issue":null,"score":1,"title":["Real-world clinical experience with benralizumab for severe eosinophilic asthma in the Czech Republic: fewer corticosteroids and better symptom control"],"author":[{"given":"Norbert","family":"Pauk","sequence":"first","affiliation":[{"name":"Department of Pneumology, University Hospital Bulovka and 3rd Faculty of Medicine, Charles University"}]},{"given":"Tomáš","family":"Valena","sequence":"additional","affiliation":[{"name":"AstraZeneca Czech Republic s.r.o"},{"name":"Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University Bratislava"}]},{"given":"Irena","family":"Krčmová","sequence":"additional","affiliation":[{"name":"Institute for Clinical Immunology and Allergology, University Hospital Hradec Králové"}]},{"given":"Lucie","family":"Heribanová","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Thomayer University Hospital and 1st Faculty of Medicine, Charles University"}]},{"given":"Beáta","family":"Hutyrová","sequence":"additional","affiliation":[{"name":"Department of Allergology and Clinical Immunology, University Hospital Olomouc"}]},{"given":"Radka","family":"Mokošová","sequence":"additional","affiliation":[{"name":"Plicníalergo, s.r.o"}]},{"given":"Martin","family":"Voříšek","sequence":"additional","affiliation":[{"name":"AstraZeneca Czech Republic s.r.o"}]},{"given":"Mirek","family":"Maruščák","sequence":"additional","affiliation":[{"name":"AstraZeneca Czech Republic s.r.o"}]}],"funder":[{"id":[{"id":"10.13039/100004325","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100004325","name":"AstraZeneca","doi-asserted-by":"publisher"},{"name":"University Hospital Bulovka"},{"name":"Charles University, Prague, Czech Republic"},{"id":[{"id":"10.13039/100007397","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,5]]},"member":"301","prefix":"10.1080","source":"Crossref","volume":null,"created":{"date-time":"2025-12-27T14:39:47Z","timestamp":1766846387000,"date-parts":[[2025,12,27]]},"indexed":{"date-time":"2026-01-05T19:25:46Z","timestamp":1767641146224,"date-parts":[[2026,1,5]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc-nd/4.0/","start":{"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000,"date-parts":[[2026,1,5]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.tandfonline.com/doi/full/10.1080/02770903.2025.2610346"}},"subtitle":[],"assertion":[{"name":"peerreview_statement","label":"Peer Review Statement","order":1,"value":"The publishing and review policy for this title is described in its Aims & Scope."},{"URL":"http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijas20","name":"aims_and_scope_url","label":"Aim & Scope","order":2,"value":"http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijas20"},{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-09"},{"name":"revised","group":{"name":"publication_history","label":"Publication History"},"label":"Revised","order":1,"value":"2025-12-12"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-12-23"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-05"}],"deposited":{"date-time":"2026-01-05T15:53:18Z","timestamp":1767628398000,"date-parts":[[2026,1,5]]},"issn-type":[{"type":"print","value":"0277-0903"},{"type":"electronic","value":"1532-4303"}],"published":{"date-parts":[[2026,1,5]]},"publisher":"Informa UK Limited","reference":[{"DOI":null,"key":"e_1_3_4_2_1","year":"2022","issue":null,"author":"Salajka F","volume":null,"first-page":null,"unstructured":"Salajka F, Teřl M, Prokeš M. Astma bronchiale: doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. In: Novelizace. Praha (CZ): Společnost všeobecného lékařství; 2022.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1080/02770903.2019.1619082","key":"e_1_3_4_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_4_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2024. Available from: https://ginasthma.org.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_4_5_1","year":"2023","issue":null,"author":"Teřl M","volume":null,"first-page":null,"unstructured":"Teřl M, Sedlák V, Krčmová I. Doporučený postup diagnostiky a léčby těžkého astmatu. 1st ed. Semily (CZ): Geum; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_4_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"European Medicines Agency (EMA). Fasenra. 2018. [cited 28 October 2024]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/1939-4551-7-32","key":"e_1_3_4_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(16)31322-8","key":"e_1_3_4_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(16)31324-1","key":"e_1_3_4_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1703501","key":"e_1_3_4_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1183/23120541.00009-2019","key":"e_1_3_4_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_4_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Státní ústav pro kontrolu léčiv (SÚKL). Medicinal products overviews [Internet]. [cited 24 April 2025]. Available from: https://prehledy.sukl.cz/prehled_leciv.html#/leciva/0238555.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1183/13993003.01521-2023","key":"e_1_3_4_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2023.05.047","key":"e_1_3_4_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12931-023-02439-w","key":"e_1_3_4_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12931-023-02539-7","key":"e_1_3_4_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.chest.2023.10.046","key":"e_1_3_4_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/JAA.S503048","key":"e_1_3_4_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2022.02.014","key":"e_1_3_4_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1183/23120541.00383-2023","key":"e_1_3_4_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s11882-017-0686-1","key":"e_1_3_4_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2022.02.002","key":"e_1_3_4_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jval.2023.09.1595","key":"e_1_3_4_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12890-023-02786-w","key":"e_1_3_4_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms26115288","key":"e_1_3_4_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.alit.2023.08.007","key":"e_1_3_4_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12919-021-00230-7","key":"e_1_3_4_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/JAA.S438981","key":"e_1_3_4_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.chest.2024.11.035","key":"e_1_3_4_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1080/tandf_crossmark_01","alternative-id":["10.1080/02770903.2025.2610346"],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Asthma"],"reference-count":28,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,5]]},"references-count":28,"short-container-title":["Journal of Asthma"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1080/02770903.2025.2610346","is_oa":false,"title":"Real-world clinical experience with benralizumab for severe eosinophilic asthma in the Czech Republic: fewer corticosteroids and better symptom control","updated":"2026-01-10T04:46:20+00:00","published_date":"2025-12-27","best_oa_location":null}},"created_at":"2026-01-15T20:51:27.064Z","updated_at":"2026-01-15T20:51:27.064Z","tags":[{"paper_doi":"10.1080/02770903.2025.2610346","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1080/02770903.2025.2610346","tag_type":"condition","value":"Severe Eosinophilic Asthma","value_numeric":null},{"paper_doi":"10.1080/02770903.2025.2610346","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1080/02770903.2025.2610346","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1080/02770903.2025.2610346","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1080/02770903.2025.2610346","tag_type":"study_design","value":"Cohort","value_numeric":null},{"paper_doi":"10.1080/02770903.2025.2610346","tag_type":"warning","value":"Abstract appears truncated; sample size and exact effect sizes are not provided.","value_numeric":null},{"paper_doi":"10.1080/02770903.2025.2610346","tag_type":"warning","value":"Design classification inferred as a cohort based on an observational, pre–post comparison.","value_numeric":null},{"paper_doi":"10.1080/02770903.2025.2610346","tag_type":"warning","value":"No numerical outcomes were available in the provided text.","value_numeric":null}],"summaries":{"what_studied":"Real-world outcomes from the Czech cohort of the multinational BREEZE observational study of severe eosinophilic asthma treated with benralizumab, comparing 12 months before first dose with 56 weeks after. Eligibility required a SEA diagnosis and receipt of at least one benralizumab dose; analyses used descriptive statistics with paired t-test or Wilcoxon tests.","key_result":"Benralizumab treatment was associated with reduced maintenance oral corticosteroid need, fewer exacerbations, and improved asthma control in this Czech real-world cohort.","limitations":"Observational, pre–post design without a randomized comparator; single-country (Czech) cohort limits generalizability.","practice_takeaway":"In routine Czech practice, benralizumab was linked to steroid-sparing, fewer attacks, and better asthma control over about a year in patients with severe eosinophilic asthma."}},{"doi":"10.1007/s11882-025-01242-5","pmid":"41405763","title":"Psychological and Related Factors Influencing Adherence to Biologic Therapies in Asthma: A Scoping Review","journal_title":"Current Allergy and Asthma Reports","journal_issn":"1529-7322","published_at":"2025-12-17T00:00:00.000Z","url":"https://doi.org/10.1007/s11882-025-01242-5","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-18","doi":"10.1007/s11882-025-01242-5","days":"30","issn":"1529-7322","rank":"4","field":"Clinical Medicine","score":"15","category":"Allergy","categories":["Allergy"],"_categories":["Allergy"]},"pubmed":{"doi":"10.1007/s11882-025-01242-5","title":"Psychological and Related Factors Influencing Adherence to Biologic Therapies in Asthma: A Scoping Review.","journal":"Current allergy and asthma reports","methods":"","results":"","abstract":"$32","keywords":["Adherence","Asthma","Biologic therapy","Scoping review"],"pubmed_id":"41405763","conclusions":"","publication_date":"2025-12-17T00:00:00"},"crossref":{"DOI":"10.1007/s11882-025-01242-5","URL":"https://doi.org/10.1007/s11882-025-01242-5","ISSN":["1529-7322","1534-6315"],"link":[{"URL":"https://link.springer.com/content/pdf/10.1007/s11882-025-01242-5.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/article/10.1007/s11882-025-01242-5/fulltext.html","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/content/pdf/10.1007/s11882-025-01242-5.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"1","score":1,"title":["Psychological and Related Factors Influencing Adherence to Biologic Therapies in Asthma: A Scoping Review"],"author":[{"given":"Valentina","family":"Poletti","sequence":"first","affiliation":[]},{"given":"Eleonora","family":"Volpato","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100005743","id-type":"DOI","asserted-by":"crossref"}],"DOI":"10.13039/501100005743","name":"Università Cattolica del Sacro Cuore","doi-asserted-by":"crossref"}],"issued":{"date-parts":[[2025,12]]},"member":"297","prefix":"10.1007","source":"Crossref","volume":"25","created":{"date-time":"2025-12-17T09:36:47Z","timestamp":1765964207000,"date-parts":[[2025,12,17]]},"indexed":{"date-time":"2025-12-17T09:41:48Z","timestamp":1765964508573,"date-parts":[[2025,12,17]]},"license":[{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000,"date-parts":[[2025,12,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000,"date-parts":[[2025,12,17]]},"delay-in-days":16,"content-version":"vor"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1007/s11882-025-01242-5"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"26 July 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"2 December 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"17 December 2025"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics, Consent to Participate, and Consent to Publish"},"order":2,"value":"Not applicable."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"},"order":3,"value":"The authors declare no competing interests.EV declares the winning of an ERS Long-Term Research Fellowship 2024 grant (ID Number: LTRF202404-01155), which is unrelated to this study. Therefore, the author(s) report no conflicts of interest related to this work."}],"deposited":{"date-time":"2025-12-17T09:36:52Z","timestamp":1765964212000,"date-parts":[[2025,12,17]]},"issn-type":[{"type":"print","value":"1529-7322"},{"type":"electronic","value":"1534-6315"}],"published":{"date-parts":[[2025,12]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1038/nrd3792","key":"1242_CR1","year":"2012","issue":"12","author":"G Pelaia","volume":"11","first-page":"958","unstructured":"Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11(12):958–72. https://doi.org/10.1038/nrd3792.","article-title":null,"journal-title":"Nat Rev Drug Discov","doi-asserted-by":"publisher"},{"DOI":"10.1164/RCCM.201810-1944CI","key":"1242_CR2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. AtsjournalsOrgMC McGregor, JG Krings, P Nair, M CastroAmerican J Respir Crit Care Med 2019. 2019;199:433–45. atsjournalsOrg. https://doi.org/10.1164/RCCM.201810-1944CI.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/RESP.14520","key":"1242_CR3","year":"2023","issue":null,"author":"P Ameen Shah","volume":"28","first-page":"709","unstructured":"Ameen Shah P, Brightling C, Jenkins C, Bardin P. Biologics for severe asthma—Which, when and why? Wiley Online Libr Shah, C Bright 2023. Wiley Online Libr. 2023;28:709–21. https://doi.org/10.1111/RESP.14520.","article-title":null,"journal-title":"Wiley Online Libr","doi-asserted-by":"publisher"},{"DOI":"10.1016/J.JAIP.2017.06.008","key":"1242_CR4","year":"2018","issue":null,"author":"PP Hekking","volume":"6","first-page":"108","unstructured":"Hekking PP, Amelink M, Wener RR, Bouvy ML, Bel EH. Comorbidities in difficult-to-control asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6:108–13. https://doi.org/10.1016/J.JAIP.2017.06.008.","article-title":null,"journal-title":"The Journal of Allergy and Clinical Immunology: In Practice","doi-asserted-by":"publisher"},{"DOI":"10.1183/16000617.0088-2024","key":"1242_CR5","year":"2025","issue":null,"author":"B Gyawali","volume":null,"first-page":null,"unstructured":"Gyawali B, Georas SN, Khurana S. Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev. 2025. https://doi.org/10.1183/16000617.0088-2024.","article-title":null,"journal-title":"Eur Respir Rev","doi-asserted-by":"publisher"},{"DOI":"10.1016/J.ANAI.2021.07.010","key":"1242_CR6","year":"2021","issue":null,"author":"J Trevor","volume":"127","first-page":"579","unstructured":"Trevor J, Lugogo N, Carr W, Moore WC, Soong W, Panettieri RA, et al. Severe asthma exacerbations in the United States: Incidence, characteristics, predictors, and effects of biologic treatments. Ann Allergy, Asthma Immunol. 2021;127:579-587.e1. https://doi.org/10.1016/J.ANAI.2021.07.010.","article-title":null,"journal-title":"Ann Allergy, Asthma Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ALL.15473","key":"1242_CR7","year":"2022","issue":null,"author":"G Varricchi","volume":"77","first-page":"3538","unstructured":"Varricchi G, Ferri S, Pepys J, Poto R, Spadaro G, Nappi E, et al. Biologics and airway remodeling in severe asthma. Allergy. 2022;77:3538–52. https://doi.org/10.1111/ALL.15473.","article-title":null,"journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2014.09.014","key":"1242_CR8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Darveaux J, Immunology WB-TJ of A and C, 2015 undefined. Biologics in asthma—the next step toward personalized treatment. ElsevierJ Darveaux, WW BusseThe J Allergy Clin Immunol Pract 2015•Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/j.chest.2020.10.050","key":"1242_CR9","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Maddux J, Inselman J, Jeffery M, Chest RL. Adherence to asthma biologics: implications for patient selection, step therapy, and outcomes. 2021. Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1111/HEX.70285","key":"1242_CR10","year":"2025","issue":null,"author":"E Volpato","volume":null,"first-page":null,"unstructured":"Volpato E, Poletti V, Banfi P, Bonanomi A, Pagnini F. Illness expectations and asthma symptoms: a 6-month longitudinal study. Health Expect. 2025. https://doi.org/10.1111/HEX.70285.","article-title":null,"journal-title":"Health Expect","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0954-6111(03)00029-5","key":"1242_CR11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Barton C, Clarke D, Sulaiman N, medicine MA-R. Coping as a mediator of psychosocial impediments to optimal management and control of asthma. 2003. Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1378/chest.09-1979","key":"1242_CR12","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Lavoie K, Bouthillier D, Bacon S, Lemière C, Chest JM. Psychologic distress and maladaptive coping styles in patients with severe vs moderate asthma. 2010. Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/J.JAIP.2020.08.021","key":"1242_CR13","year":"2021","issue":null,"author":"IL Riley","volume":"9","first-page":"410","unstructured":"Riley IL, Jackson B, Crabtree D, Riebl S, Que LG, Pleasants R, et al. A scoping review of international barriers to asthma medication adherence mapped to the theoretical domains framework. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9:410-418.e4. https://doi.org/10.1016/J.JAIP.2020.08.021.","article-title":null,"journal-title":"The Journal of Allergy and Clinical Immunology: In Practice","doi-asserted-by":"publisher"},{"DOI":"10.11124/JBIES-21-00242","key":"1242_CR14","year":"2022","issue":null,"author":"MDJ Peters","volume":"20","first-page":"953","unstructured":"Peters MDJ, Godfrey C, McInerney P, Khalil H, Larsen P, Marnie C, et al. Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022;20:953–68. https://doi.org/10.11124/JBIES-21-00242.","article-title":null,"journal-title":"JBI Evid Synth","doi-asserted-by":"publisher"},{"DOI":"10.1371/JOURNAL.PONE.0278434","key":"1242_CR15","year":"2024","issue":null,"author":"SL Chan","volume":"19","first-page":null,"unstructured":"Chan SL, Ho CZH, Khaing NEE, Ho E, Pong C, Guan JS, et al. Frameworks for measuring population health: a scoping review. PLoS One. 2024;19:e0278434. https://doi.org/10.1371/JOURNAL.PONE.0278434.","article-title":null,"journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1080/1364557032000119616","key":"1242_CR16","year":"2005","issue":null,"author":"H Arksey","volume":"8","first-page":"19","unstructured":"Arksey H. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32. https://doi.org/10.1080/1364557032000119616.","article-title":null,"journal-title":"Int J Soc Res Methodol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jclinepi.2020.03.016","key":"1242_CR17","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"McGowan J, Straus S, Moher D, EL-JC. Reporting scoping reviews-PRISMA ScR extension. Acad McGowan, S Straus, D Moher, EV Langlois, KK O’Brien, T Horsley, A Aldcroft, W ZarinJ Clin Epidemiol. 2020. AcademiaEdu n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1093/AJHP/ZXAB392","key":"1242_CR18","year":"2022","issue":null,"author":"J Loucks","volume":"79","first-page":"492","unstructured":"Loucks J, Zuckerman AD, Berni A, Saulles A, Thomas G, Alonzo A. Proportion of days covered as a measure of medication adherence. Am J Health-Syst Pharm. 2022;79:492–6. https://doi.org/10.1093/AJHP/ZXAB392.","article-title":null,"journal-title":"Am J Health-Syst Pharm","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.anai.2023.07.017","key":"1242_CR19","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Ledford D, Soong W, Carr W, Trevor J, LT-A of A. Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results. 2023. Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaip.2022.05.022","key":"1242_CR20","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Osazuwa-Peters O, Greiner M. AO-TJ of A. Factors related to biologic adherence and outcomes among moderate-to-severe asthma patients. 2022. Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaip.2022.07.016","key":"1242_CR21","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Bender B, Oppenheimer J, George M. RB-TJ of A, Assessment of real-world escalation to biologics in US patients with asthma. 2022. Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A6010","key":"1242_CR22","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Gleeson P, Morales K, Hvisdas C. AL-TJ of A, Factors associated with asthma biologic prescribing and primary adherence among adults in a large health system. 2023. Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"1242_CR23","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Granda P, Villamañán E, Carpio C. DL-F, Adherence to inhalers in patients with severe asthma treated with anti-interleukin-5 biologics. 2022. Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.2147/JAA.S328653","key":"1242_CR24","year":"2022","issue":null,"author":"AN Menzies-Gow","volume":"15","first-page":"63","unstructured":"Menzies-Gow AN, McBrien C, Unni B, Porsbjerg CM, Al-Ahmad M, Ambrose CS, et al. Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study. Taylor Fr. 2022;15:63–78. https://doi.org/10.2147/JAA.S328653.","article-title":null,"journal-title":"Taylor Fr","doi-asserted-by":"publisher"},{"DOI":"10.2147/JAA.S468068","key":"1242_CR25","year":"2024","issue":null,"author":"TT Le","volume":"17","first-page":"1055","unstructured":"Le TT, Price DB, Erhard C, Cook B, Quinton A, Katial R, et al. Disease burden and access to biologic therapy in patients with severe asthma, 2017–2022: an analysis of the international severe asthma registry. Taylor Fr. 2024;17:1055–69. https://doi.org/10.2147/JAA.S468068.","article-title":null,"journal-title":"Taylor Fr.","doi-asserted-by":"publisher"},{"DOI":"10.1183/23120541.00560-2023","key":"1242_CR26","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Crimi C, Calabrese C, D’Amato M. FB-EO. Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey. 2023. PmcNcbiNlmNihGov n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/J.JAIP.2019.08.024","key":"1242_CR27","year":"2020","issue":null,"author":"JW Inselman","volume":"8","first-page":"549","unstructured":"Inselman JW, Jeffery MM, Maddux JT, Shah ND, Rank MA. Trends and disparities in asthma biologic use in the United States. J Allergy Clin Immunol Pract. 2020;8:549-554.e1. https://doi.org/10.1016/J.JAIP.2019.08.024.","article-title":null,"journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"publisher"},{"DOI":"10.1080/02770903.2021.1971700","key":"1242_CR28","year":"2022","issue":null,"author":"J Silver","volume":"59","first-page":"1839","unstructured":"Silver J, Bogart M, Molfino NA, Siddall J, Small M, Hanson M, et al. Factors leading to discontinuation of biologic therapy in patients with severe asthma. J Asthma. 2022;59:1839–49. https://doi.org/10.1080/02770903.2021.1971700.","article-title":null,"journal-title":"J Asthma","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2018.07.007","key":"1242_CR29","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Corren J, Clinical RP-TJ of A and, undefined. How important is adherence to inhaled medications before starting a biologic therapy for asthma? 2018. Jaci-InpracticeOrg n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaip.2022.08.034","key":"1242_CR30","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Stempel D, In SS-TJ of A and CI, undefined. Adding a biologic to asthma therapy: the role of adherence in selecting the right patient. 2022. Elsevier n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.2147/PPA.S198953","key":"1242_CR31","year":"2019","issue":null,"author":"HL Gelhorn","volume":"13","first-page":"1253","unstructured":"Gelhorn HL, Balantac Z, Ambrose CS, Chung YN, Stone B. Patient and physician preferences for attributes of biologic medications for severe asthma. Patient Prefer Adherence. 2019;13:1253–68. https://doi.org/10.2147/PPA.S198953.","article-title":null,"journal-title":"Patient Prefer Adherence","doi-asserted-by":"publisher"},{"DOI":"10.1007/978-3-319-30994-1_2","key":"1242_CR32","year":"2016","issue":null,"author":"I Aslam","volume":null,"first-page":"7","unstructured":"Aslam I, Farhangian ME, Feldman SR. Models of Adherence. In: Adherence in Dermatology. 2016. p. 7–16. https://doi.org/10.1007/978-3-319-30994-1_2.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"1242_CR33","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Christensen A. Patient adherence to medical treatment regimens: Bridging the gap between behavioral science and biomedicine. 2004.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.iac.2004.09.005","key":"1242_CR34","year":"2005","issue":null,"author":"BG Bender","volume":"25","first-page":"107","unstructured":"Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2005;25:107–30. https://doi.org/10.1016/j.iac.2004.09.005.","article-title":null,"journal-title":"Immunol Allergy Clin North Am","doi-asserted-by":"publisher"},{"DOI":"10.1080/02770903.2016.1229335","key":"1242_CR35","year":"2017","issue":null,"author":"J Yorke","volume":"54","first-page":"543","unstructured":"Yorke J, Adair P, Doyle AM, Dubrow-Marshall L, Fleming S, Holmes L, et al. A randomised controlled feasibility trial of group cognitive behavioural therapy for people with severe asthma. J Asthma. 2017;54:543–54. https://doi.org/10.1080/02770903.2016.1229335.","article-title":null,"journal-title":"J Asthma","doi-asserted-by":"publisher"},{"DOI":"10.3390/life11111113","key":"1242_CR36","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Ambrosino N, Life PP-, 2021 undefined. Using telemedicine to monitor the patient with chronic respiratory failure. MdpiComN Ambrosino, P PierucciLife, 2021•mdpiCom n.d.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.2147/PPA.S165404","key":"1242_CR37","year":"2018","issue":null,"author":"LL Zullig","volume":"12","first-page":"1225","unstructured":"Zullig LL, Blalock DV, Dougherty S, Henderson R, Ha CC, Oakes MM, et al. The new landscape of medication adherence improvement: where population health science meets precision medicine. Patient Prefer Adherence. 2018;12:1225–30. https://doi.org/10.2147/PPA.S165404.","article-title":null,"journal-title":"Patient Prefer Adherence","doi-asserted-by":"publisher"},{"DOI":"10.1093/FAMPRA/CMW122","key":"1242_CR38","year":"2017","issue":null,"author":"H Tapp","volume":"34","first-page":"353","unstructured":"Tapp H, Derkowski D, Calvert M, Welch M, Spencer S. Patient perspectives on engagement in shared decision-making for asthma care. Fam Pract. 2017;34:353–7. https://doi.org/10.1093/FAMPRA/CMW122.","article-title":null,"journal-title":"Fam Pract","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1242"],"article-number":"60","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Current Allergy and Asthma Reports"],"published-print":{"date-parts":[[2025,12]]},"reference-count":38,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,17]]},"references-count":38,"short-container-title":["Curr Allergy Asthma Rep"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1007/s11882-025-01242-5","is_oa":true,"title":"Psychological and Related Factors Influencing Adherence to Biologic Therapies in Asthma: A Scoping Review","updated":"2025-12-21T03:41:08+00:00","published_date":"2025-12-01","best_oa_location":{"url":"https://link.springer.com/content/pdf/10.1007/s11882-025-01242-5.pdf","pmh_id":null,"url_for_pdf":"https://link.springer.com/content/pdf/10.1007/s11882-025-01242-5.pdf","url_for_landing_page":"https://doi.org/10.1007/s11882-025-01242-5"}}},"created_at":"2026-01-09T17:12:27.221Z","updated_at":"2026-01-17T09:03:27.421Z","tags":[{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"condition","value":"Asthma","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"generic","value":"benralizumab","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"generic","value":"dupilumab","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"generic","value":"mepolizumab","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"generic","value":"omalizumab","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"generic","value":"reslizumab","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"sample_size","value":"n=14 studies","value_numeric":14},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"study_design","value":"Scoping Review","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"warning","value":"Adherence estimates and rankings by biologic conflict across studies (e.g., dupilumab lowest vs highest), reflecting differing methods and populations.","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"warning","value":"Psychological variables were often not primary outcomes and may be undermeasured.","value_numeric":null},{"paper_doi":"10.1007/s11882-025-01242-5","tag_type":"warning","value":"This is a scoping review of predominantly observational data and did not include a formal risk-of-bias assessment.","value_numeric":null}],"summaries":{"what_studied":"A scoping review mapped psychological and related biopsychosocial factors that influence adherence to asthma biologics across 14 studies published 2018–2025, mostly observational/retrospective and U.S.-based.","key_result":"Adherence was generally moderate to high but variable: reported PDC medians/means clustered around 0.75–0.87; 79% continued the same biologic ≥6 months, primary adherence was 84.9%, and discontinuation reached 29.8% in one study; home/hybrid delivery showed higher median PDC than clinic (0.83 vs 0.75).","limitations":"Heterogeneous designs, populations, and adherence measures limited comparability; most data were U.S.-centric; psychological factors were often secondary and undermeasured; no formal risk-of-bias assessment was performed.","practice_takeaway":"Assess and address depression, needle fear, illness denial, and stigma; use shared decision-making and patient education; mitigate system barriers (costs, authorizations) and consider home or less-frequent dosing models, which were linked to better adherence in some studies."}},{"doi":"10.1111/all.70187","pmid":"41363469","title":"Drug Survival in Atopic Dermatitis: Comparison of Biologics and\n JAK\n Inhibitors in the\n BioDay\n Registry","journal_title":"Allergy","journal_issn":"0105-4538","published_at":"2025-12-09T00:00:00.000Z","url":"https://doi.org/10.1111/all.70187","source_score":26,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-08","doi":"10.1111/all.70187","days":"30","issn":"0105-4538","rank":"1","field":"Clinical Medicine","score":"26","category":"Allergy","categories":["Allergy"],"_categories":["Allergy"]},"pubmed":{"doi":"10.1111/all.70187","title":"Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry.","journal":"Allergy","methods":"","results":"","abstract":"","keywords":["atopic dermatitis","biologics","dermatology","epidemiology","personlized medicine"],"pubmed_id":"41363469","conclusions":"","publication_date":"2025-12-09T00:00:00"},"crossref":{"DOI":"10.1111/all.70187","URL":"https://doi.org/10.1111/all.70187","ISSN":["0105-4538","1398-9995"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.70187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Drug Survival in Atopic Dermatitis: Comparison of Biologics and\n JAK\n Inhibitors in the\n BioDay\n Registry"],"author":[{"given":"Lian F.","family":"van der Gang","sequence":"first","affiliation":[{"name":"National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Centre Utrecht Utrecht the Netherlands"}]},{"given":"Celeste M.","family":"Boesjes","sequence":"additional","affiliation":[{"name":"National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Centre Utrecht Utrecht the Netherlands"}]},{"given":"Nicolaas P. A.","family":"Zuithoff","sequence":"additional","affiliation":[{"name":"Julius Centre for Health Sciences and Primary Care University Medical Centre Utrecht Utrecht the Netherlands"}]},{"given":"Inge","family":"Haeck","sequence":"additional","affiliation":[{"name":"National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Centre Utrecht Utrecht the Netherlands"}]},{"given":"Octavian","family":"Bacoş‐Cosma","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Centre Groningen Groningen the Netherlands"}]},{"given":"Laura","family":"Loman","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Centre Groningen Groningen the Netherlands"}]},{"given":"Keneshka","family":"Atash","sequence":"additional","affiliation":[{"name":"National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Centre Utrecht Utrecht the Netherlands"}]},{"given":"Veroniek","family":"Harbers","sequence":"additional","affiliation":[{"name":"Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands"}]},{"given":"Simone","family":"Stadhouders","sequence":"additional","affiliation":[{"name":"Department of Dermatology Reinier de Graaf Hospital Delft the Netherlands"}]},{"given":"Albert J.","family":"Oosting","sequence":"additional","affiliation":[{"name":"Department of Dermatology Spaarne Gasthuis Hoofddorp the Netherlands"}]},{"given":"Anneke M. T.","family":"van Lynden‐van Nes","sequence":"additional","affiliation":[{"name":"Department of Dermatology Meander Medical Centre Amersfoort the Netherlands"}]},{"given":"Klaziena","family":"Politiek","sequence":"additional","affiliation":[{"name":"Department of Dermatology Frisius Medical Centre Leeuwarden the Netherlands"}]},{"given":"Antoni","family":"Gostynski","sequence":"additional","affiliation":[{"name":"Department of Dermatology Maastricht University Medical Centre+ Maastricht the Netherlands"},{"name":"GROW ‐ Research Institute for Oncology and Reproduction Maastricht University Maastricht the Netherlands"}]},{"given":"Wianda A.","family":"Christoffers","sequence":"additional","affiliation":[{"name":"Department of Dermatology Isala Hospital Zwolle the Netherlands"}]},{"given":"Floor M.","family":"Garritsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Haga Hospital Den Haag the Netherlands"}]},{"given":"Annebeth","family":"Flinterman","sequence":"additional","affiliation":[{"name":"Department of Dermatolog Diakonessenhuis Utrecht the Netherlands"}]},{"given":"Wouter R. H.","family":"Touwslager","sequence":"additional","affiliation":[{"name":"Department of Dermatology Catharina Hospital Eindhoven the Netherlands"}]},{"given":"Berit","family":"Velstra","sequence":"additional","affiliation":[{"name":"Department of Dermatology St Antonius Hospital Nieuwegein the Netherlands"}]},{"given":"Shiarra M.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Dermatology IJsselland Hospital Capelle aan den IJssel the Netherlands"}]},{"given":"Francine C.","family":"van Erp","sequence":"additional","affiliation":[{"name":"Department of Dermatology TerGooi Medical Centre Hilversum the Netherlands"}]},{"given":"Annemie F. S.","family":"Galimont‐Collen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Bravis Hospital Bergen op Zoom the Netherlands"}]},{"given":"Marie‐Louise A.","family":"Schuttelaar","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Centre Groningen Groningen the Netherlands"}]},{"given":"Marlies","family":"de Graaf","sequence":"additional","affiliation":[{"name":"National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Centre Utrecht Utrecht the Netherlands"}]},{"given":"Marjolein S.","family":"de Bruin‐Weller","sequence":"additional","affiliation":[{"name":"National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Centre Utrecht Utrecht the Netherlands"}]}],"issued":{"date-parts":[[2025,12,9]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-12-09T12:10:26Z","timestamp":1765282226000,"date-parts":[[2025,12,9]]},"indexed":{"date-time":"2025-12-09T12:21:25Z","timestamp":1765282885120,"date-parts":[[2025,12,9]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000,"date-parts":[[2025,12,9]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/all.70187"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-07-29"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-11-28"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-12-09"}],"deposited":{"date-time":"2025-12-09T12:10:29Z","timestamp":1765282229000,"date-parts":[[2025,12,9]]},"issn-type":[{"type":"print","value":"0105-4538"},{"type":"electronic","value":"1398-9995"}],"published":{"date-parts":[[2025,12,9]]},"publisher":"Wiley","reference":[{"DOI":"10.1038/jid.2015.171","key":"e_1_2_1_9_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/978-1-4757-2555-1","key":"e_1_2_1_9_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12982‐017‐0060‐8","key":"e_1_2_1_9_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_1_9_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"T. M.Therneau C.Crowson andE.Atkinson “A Package for Survival Analysis in S ”Version 2.38. 2015. CRANR‐projectorgpackagesurvival.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jdv.20581","key":"e_1_2_1_9_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v105.41504","key":"e_1_2_1_9_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/all.70187"],"article-number":"all.70187","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Allergy"],"reference-count":6,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,9]]},"references-count":6,"short-container-title":["Allergy"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/all.70187","is_oa":true,"title":"Drug Survival in Atopic Dermatitis: Comparison of Biologics and\n JAK\n Inhibitors in the\n BioDay\n Registry","updated":"2025-12-11T01:31:13+00:00","published_date":"2025-12-09","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/all.70187","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/all.70187","url_for_landing_page":"https://doi.org/10.1111/all.70187"}}},"created_at":"2026-01-08T08:12:02.165Z","updated_at":"2026-01-09T17:12:27.221Z","tags":[{"paper_doi":"10.1111/all.70187","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1111/all.70187","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1111/all.70187","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1111/all.70187","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1111/all.70187","tag_type":"study_design","value":"Cohort","value_numeric":null},{"paper_doi":"10.1111/all.70187","tag_type":"warning","value":"No sample size, timeframe, or outcomes were provided in the text.","value_numeric":null},{"paper_doi":"10.1111/all.70187","tag_type":"warning","value":"Only the article title and citation were available; no abstract, methods, or results to summarize.","value_numeric":null},{"paper_doi":"10.1111/all.70187","tag_type":"warning","value":"Study design inferred from the mention of a registry; classification may be imprecise.","value_numeric":null}],"summaries":{"what_studied":"Compared drug survival of biologics versus JAK inhibitors for atopic dermatitis using the BioDay registry."}}],"initialOffset":8,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"category","value":"Allergy"},{"tag_type":"modality","value":"Biologic"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Allergy","href":"/hub/Allergy"},{"name":"modality: Biologic","metadata":{"type":"modality","value":"Biologic"}}],"hrefConfig":{"basePath":"/hub/Allergy/papers","webViewQueryParams":{"hub_ctx":"category_tag","hub_category":"Allergy","hub_tag_type":"modality","hub_tag_value":"Biologic"}}}]]

Papers